RxParadigm was founded by a team of seasoned Pharmacy Benefit Management Professionals to restore competitiveness and simplify the marketplace with ingenuity, collaboration and robust technology.
CEO and Chairman
Mesfin Tegenu is a nationally recognized thought leader in Pharmacy Benefit Management (PBM), who over a 25-year career, has negotiated several billion dollars in rebates with major drug manufacturers. An early pioneer of PBM, Mesfin Tegenu had previously built one of the country’s leading PBM organizations, transforming it from near start-up to an industry leader.
From his beginning as a clinical pharmacist, Mesfin Tegenu’s main focus has always been on developing innovative approaches that improve patient outcomes while reducing total cost of care. This vision often placed him at odds as the industry became less transparent and less patient centric.
His frustration led him to found RxParadigm, Inc. a new entrant into the market to facilitate the paradigm shift in the PBM marketplace, which aims to disrupt the industry by employing a never-before-available level of transparency into drug pricing and reimbursement. RxParadigm is the first pharmaceutical group purchasing entity/organization that returns 100% of drug rebates directly to its family of member PBMs and payers who can deploy those savings to improve their competitive standings, create outcome-based service offerings, and save patients and insurers money while delivering real value to the marketplace.
A regular speaker, who is frequently cited by leading trade journals for his perspectives on drug access, pricing, and management, Mesfin Tegenu immigrated from Ethiopia before earning a master’s degree from St. John’s University in Queens, New York. Tegenu holds a bachelor’s degree in pharmacy from Addis Ababa University in Addis Ababa, Ethiopia.
Chris Chan, Pharm.D.
Chief Clinical & Pharmacy Officer
Chris Chan is the Chief Clinical & Pharmacy Officer of RxParadigm. He is also the co-founder of Gojji, Inc, a pharmacist-led chronic disease management company. Chris has more than 17 years of experiences in pharmacy benefit management. Previously, he was the Chief Pharmacist at a Medicaid and Medicare Plan. He has received numerous awards, including the Pharmacy Benefit Management Institute (PBMI) Excellence Award for its Innovative Community Pharmacy P4P program. Chris is passionate about improving quality of care, promote medication optimization & safety, and clinical outcomes through innovative benefit and program design.
He holds a bachelor’s degrees in chemistry and Biology from the University of California, Irvine, a Doctor of Pharmacy Degree from the University of Southern California.
Joseph E Mascelli is the owner and President of Mascelli Financial Associates — a professional accounting and tax preparation firm that has been in business since 1997. He received his bachelor’s degree in accounting and his MBA from Wilmington College. He began his career as Controller and advanced to Plant Manager for Van den Bergh Foods, a subsidiary of Unilever. He managed two operations, one in Northern New Jersey and the other in Southern New Jersey.
After a 24-year career in the corporate world, he started his own accounting and tax preparation business. He grew this business from the ground up to include over 400 tax and business clients.
Senior Director, Clinical research and Analysis
Stephanie Do is Senior Director of Clinical Research and Analysis for RxParadigm. After completing her PharmD training, she has dedicated her career to all facets of managed care, pharmacy operations, clinical, and pharmacy benefit management. Stephanie has a wide scope of expertise, including Medicaid and Medicare Part D formulary development and management, drug utilization review, pharmacy system implementation and change management, regulatory compliance, PBM oversight and vendor relations.
Stephanie has a Bachelor of Science degree from Pepperdine University, a Doctor of Pharmacy (PharmD) from Thomas Jefferson University, and a Master of Public Health degree from Loma Linda University.
Allen has extensive experience in the various aspects of regulations working with corporations, health care providers, and Managed Care Clients.
In the past 20 years, Allen has worked effectively in matters related to PBMs, pharmacies, specialty drug providers, PSAOs, HITs, and pharmaceutical companies. Allen has unique expertise in designing Risk based PBM models.
Mason is a 7-year NBA veteran and former Academic All American at Duke University. He is an active angel investor and serves as an advisor to healthcare startups as well as life-sciences accelerator: The Prysm Institute.
Priscilla is currently the Group Executive Marketing and Corporate Affairs of Commonwealth Bank of Australia and CEO of Emerge.me. Prior to this, Priscilla was Senior Vice President and Chief Marketing Officer at AXA Financial in the US, where she had responsibility for transforming the end-to-end customer experience, as well as leading global digital marketing initiatives.
She has also held executive leadership roles at AmeriHealth Caritas, Sun Life Financial US, and Lincoln National Corporation, with responsibility for leading business units, stakeholder engagement, marketing, corporate affairs, investor relations and business development functions.
Dr. Sherief Shaaban serves as the Vice President of Strategic Ventures for Catalent Pharma Solutions – the world leader in advanced drug delivery technologies and development services for pharmaceutical, biotechnology, and consumer health companies with revenues of $2.7 billion.
Prior to this he served as Vice President, Market Access National Accounts at Novo Nordisk where he led the managed care and trade account teams responsible for establishing strategic partnerships with the largest health plans and PBMs representing over 85% of Novo Nordisk US revenue.
Dr. Shaaban also led the B2B Managed Markets team at Eli Lilly & Company for the Eastern Region with responsibility for managed care organizations, Medicare Part D plans, Medicaid departments, and managed Medicaid plans, which in total represented significant revenues for Lilly.